Overview | Medtronic

Creating Long-Term Shareholder Value

Medtronic is uniquely positioned to create long-term value in healthcare. The combination of Medtronic and Covidien creates a robust, market-leading medical technology and services company with a comprehensive product portfolio, broad geographic reach, and diversified growth profile. We believe Covidien meaningfully complements and accelerates our three primary strategies - therapy innovation, globalization, and economic value. We are focused on delivering a strong launch cadence of leading healthcare innovation, addressing the inequity in healthcare access globally, and becoming a leader in the changing value-based healthcare landscape with offerings that deliver both clinical and economic value to a broader set of partners around the world, including physicians, hospital systems, payers, governments, and patients. The addition of Covidien is expected to not only strengthen our long-term market competitiveness, but also increase our financial strength and capital deployment flexibility, driving further sustainability and consistency in our long-term performance. We believe that execution and reliable performance, combined with our disciplined allocation of capital, will create long-term value for our shareholders.

Latest Investor Information

April 15, 2015
Shareholders still holding Medtronic, Inc. certificates or Direct Registered Accounts at Wells Fargo Shareowner Services - You will not receive your dividend payments on your Medtronic plc holdings until you exchange your shares. Click here for more info.
March 11, 2015
Medtronic plc at the Barclays Global Healthcare Conference

Latest Press Releases

April 30, 2015Medtronic Initiates Study Evaluating Potential of Combination of Pulmonary Vein Isolation and Renal Denervation for Atrial Fibrillation
April 29, 2015Endurant AAA Stent Graft System from Medtronic Delivers Consistently Strong Results in Abdominal Aortic Aneurysms with Short and Standard 'Neck' Lengths
April 27, 2015Medtronic Announces Consent Decree with FDA for the Synchromed Drug Infusion System and the Neuromodulation Quality System
April 27, 2015Medtronic Starts Clinical Study of Endurant Evo AAA Stent Graft System for Endovascular Treatment of Abdominal Aortic Aneurysms
Read More
img.alt

Sustainability Index Endorsements

Read more about our Sustainability efforts.

READ MORE
 
img.alt

Medtronic Spotlight

AdvaMed’s Lifetime Achievement Award tribute to Medtronic founder Earl Bakken.

Play Video
 
img.alt

Focus on Patients

The personal connection between Medtronic plc, its employees and patients.

Play Video
 
img.alt

History of Medtronic

A video history of the company.

Play Video

Investor Contacts

Stock Transfer Agent

Wells Fargo Shareowner Services
+1 888-648-8154

Medtronic Investor Relations Department

investor.relations@medtronic.com

+1 763-505-2692

Jeff Warren

Vice President, Investor Relations

Ryan Weispfenning

Senior Director, Investor Relations

View All
X